Literature DB >> 25713287

International Union of Basic and Clinical Pharmacology. XCIII. The parathyroid hormone receptors--family B G protein-coupled receptors.

Thomas J Gardella1, Jean-Pierre Vilardaga2.   

Abstract

The type-1 parathyroid hormone receptor (PTHR1) is a family B G protein-coupled receptor (GPCR) that mediates the actions of two polypeptide ligands; parathyroid hormone (PTH), an endocrine hormone that regulates the levels of calcium and inorganic phosphate in the blood by acting on bone and kidney, and PTH-related protein (PTHrP), a paracrine-factor that regulates cell differentiation and proliferation programs in developing bone and other tissues. The type-2 parathyroid hormone receptor (PTHR2) binds a peptide ligand, called tuberoinfundibular peptide-39 (TIP39), and while the biologic role of the PTHR2/TIP39 system is not as defined as that of the PTHR1, it likely plays a role in the central nervous system as well as in spermatogenesis. Mechanisms of action at these receptors have been explored through a variety of pharmacological and biochemical approaches, and the data obtained support a basic "two-site" mode of ligand binding now thought to be used by each of the family B peptide hormone GPCRs. Recent crystallographic studies on the family B GPCRs are providing new insights that help to further refine the specifics of the overall receptor architecture and modes of ligand docking. One intriguing pharmacological finding for the PTHR1 is that it can form surprisingly stable complexes with certain PTH/PTHrP ligand analogs and thereby mediate markedly prolonged cell signaling responses that persist even when the bulk of the complexes are found in internalized vesicles. The PTHR1 thus appears to be able to activate the Gα(s)/cAMP pathway not only from the plasma membrane but also from the endosomal domain. The cumulative findings could have an impact on efforts to develop new drug therapies for the PTH receptors.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25713287      PMCID: PMC4394688          DOI: 10.1124/pr.114.009464

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  263 in total

1.  Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: detection, and pharmacological evaluation by peptide ligands.

Authors:  Sam R J Hoare; Susan K Sullivan; Anil Pahuja; Nicholas Ling; Paul D Crowe; Dimitri E Grigoriadis
Journal:  Peptides       Date:  2003-12       Impact factor: 3.750

2.  Characterization of parathyroid hormone receptors in canine renal cortical plasma membranes using a radioiodinated sulfur-free hormone analogue. Correlation of binding with adenylate cyclase activity.

Authors:  G V Segre; M Rosenblatt; B L Reiner; J E Mahaffey; J T Potts
Journal:  J Biol Chem       Date:  1979-08-10       Impact factor: 5.157

3.  A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide.

Authors:  H Jüppner; A B Abou-Samra; M Freeman; X F Kong; E Schipani; J Richards; L F Kolakowski; J Hock; J T Potts; H M Kronenberg
Journal:  Science       Date:  1991-11-15       Impact factor: 47.728

Review 4.  Passing the baton in class B GPCRs: peptide hormone activation via helix induction?

Authors:  Christoph Parthier; Steffen Reedtz-Runge; Rainer Rudolph; Milton T Stubbs
Journal:  Trends Biochem Sci       Date:  2009-05-14       Impact factor: 13.807

5.  Constitutive activation of the cyclic adenosine 3',5'-monophosphate signaling pathway by parathyroid hormone (PTH)/PTH-related peptide receptors mutated at the two loci for Jansen's metaphyseal chondrodysplasia.

Authors:  E Schipani; G S Jensen; J Pincus; R A Nissenson; T J Gardella; H Jüppner
Journal:  Mol Endocrinol       Date:  1997-06

6.  Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors.

Authors:  T J Gardella; M D Luck; G S Jensen; E Schipani; J T Potts; H Jüppner
Journal:  Endocrinology       Date:  1996-09       Impact factor: 4.736

Review 7.  Nanobody stabilization of G protein-coupled receptor conformational states.

Authors:  Jan Steyaert; Brian K Kobilka
Journal:  Curr Opin Struct Biol       Date:  2011-07-21       Impact factor: 6.809

8.  Parathyroid hormone-receptor interactions identified directly by photocross-linking and molecular modeling studies.

Authors:  A Bisello; A E Adams; D F Mierke; M Pellegrini; M Rosenblatt; L J Suva; M Chorev
Journal:  J Biol Chem       Date:  1998-08-28       Impact factor: 5.157

9.  Mapping peptide hormone-receptor interactions using a disulfide-trapping approach.

Authors:  Paul Monaghan; Beena E Thomas; Iwona Woznica; Angela Wittelsberger; Dale F Mierke; Michael Rosenblatt
Journal:  Biochemistry       Date:  2008-05-07       Impact factor: 3.162

10.  Analysis of parathyroid hormone's principal receptor-binding region by site-directed mutagenesis and analog design.

Authors:  T J Gardella; A K Wilson; H T Keutmann; R Oberstein; J T Potts; M Kronenberg; S R Nussbaum
Journal:  Endocrinology       Date:  1993-05       Impact factor: 4.736

View more
  33 in total

1.  Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.

Authors:  P D'Amelio; F Sassi; I Buondonno; G Fornelli; E Spertino; L D'Amico; M Marchetti; M Lucchiari; I Roato; G C Isaia
Journal:  Osteoporos Int       Date:  2015-06-12       Impact factor: 4.507

2.  Ca2+ allostery in PTH-receptor signaling.

Authors:  Alex D White; Fei Fang; Frédéric G Jean-Alphonse; Lisa J Clark; Hyun-Jung An; Hongda Liu; Yang Zhao; Shelley L Reynolds; Sihoon Lee; Kunhong Xiao; Ieva Sutkeviciute; Jean-Pierre Vilardaga
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

3.  Structure and dynamics of the active human parathyroid hormone receptor-1.

Authors:  Li-Hua Zhao; Shanshan Ma; Ieva Sutkeviciute; Dan-Dan Shen; X Edward Zhou; Parker W de Waal; Chen-Yao Li; Yanyong Kang; Lisa J Clark; Frederic G Jean-Alphonse; Alex D White; Dehua Yang; Antao Dai; Xiaoqing Cai; Jian Chen; Cong Li; Yi Jiang; Tomoyuki Watanabe; Thomas J Gardella; Karsten Melcher; Ming-Wei Wang; Jean-Pierre Vilardaga; H Eric Xu; Yan Zhang
Journal:  Science       Date:  2019-04-12       Impact factor: 47.728

4.  Studying the regulation of endosomal cAMP production in GPCR signaling.

Authors:  Alexandre Gidon; Timothy N Feinstein; Kunhong Xiao; Jean-Pierre Vilardaga
Journal:  Methods Cell Biol       Date:  2015-12-24       Impact factor: 1.441

Review 5.  PTH/PTHrP Receptor Signaling, Allostery, and Structures.

Authors:  Ieva Sutkeviciute; Lisa J Clark; Alex D White; Thomas J Gardella; Jean-Pierre Vilardaga
Journal:  Trends Endocrinol Metab       Date:  2019-11       Impact factor: 12.015

Review 6.  Advances in therapeutic peptides targeting G protein-coupled receptors.

Authors:  Anthony P Davenport; Conor C G Scully; Chris de Graaf; Alastair J H Brown; Janet J Maguire
Journal:  Nat Rev Drug Discov       Date:  2020-03-19       Impact factor: 84.694

7.  Receptor selectivity from minimal backbone modification of a polypeptide agonist.

Authors:  Shi Liu; Ross W Cheloha; Tomoyuki Watanabe; Thomas J Gardella; Samuel H Gellman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-15       Impact factor: 11.205

8.  PTH Signaling and Epigenetic Control of Bone Remodeling.

Authors:  Florante Ricarte; Teruyo Nakatani; Nicola Partridge
Journal:  Curr Mol Biol Rep       Date:  2016-02-03

9.  Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist.

Authors:  Ross W Cheloha; Tomoyuki Watanabe; Thomas Dean; Samuel H Gellman; Thomas J Gardella
Journal:  ACS Chem Biol       Date:  2016-08-17       Impact factor: 5.100

10.  Site-specific polyubiquitination differentially regulates parathyroid hormone receptor-initiated MAPK signaling and cell proliferation.

Authors:  Qiangmin Zhang; Kunhong Xiao; Hongda Liu; Lei Song; Jennifer C McGarvey; W Bruce Sneddon; Alessandro Bisello; Peter A Friedman
Journal:  J Biol Chem       Date:  2018-02-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.